fradafiban

Fradafiban is a small molecule drug that acts as a potent and reversible antagonist of the platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor, also known as the fibrinogen receptor. By blocking this receptor on platelets, fradafiban inhibits platelet aggregation and thrombus formation. It was developed primarily for cardiovascular indications such as unstable angina pectoris and thrombosis. Fradafiban itself has limited oral bioavailability due to its high polarity; therefore, an orally active prodrug called lefradafiban was also developed to improve absorption. Both compounds were investigated in clinical trials up to phase II but development was discontinued due to bleeding risks and lack of sufficient efficacy compared with other agents[1][4][6].

Other names

fradafibanum148396-36-5UNII-DQ0H2B8YKNUNII-DQ-0H2B8YKNUNII-DQ 0H2B8YKN